SG11202107663UA - Lilrb3-binding molecules and uses therefor - Google Patents

Lilrb3-binding molecules and uses therefor

Info

Publication number
SG11202107663UA
SG11202107663UA SG11202107663UA SG11202107663UA SG11202107663UA SG 11202107663U A SG11202107663U A SG 11202107663UA SG 11202107663U A SG11202107663U A SG 11202107663UA SG 11202107663U A SG11202107663U A SG 11202107663UA SG 11202107663U A SG11202107663U A SG 11202107663UA
Authority
SG
Singapore
Prior art keywords
lilrb3
binding molecules
uses therefor
therefor
molecules
Prior art date
Application number
SG11202107663UA
Inventor
Richard Brokx
Jacqueline M Mason
Mark R Bray
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SG11202107663UA publication Critical patent/SG11202107663UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202107663UA 2019-01-18 2020-01-16 Lilrb3-binding molecules and uses therefor SG11202107663UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794064P 2019-01-18 2019-01-18
PCT/CA2020/050042 WO2020146946A1 (en) 2019-01-18 2020-01-16 Lilrb3-binding molecules and uses therefor

Publications (1)

Publication Number Publication Date
SG11202107663UA true SG11202107663UA (en) 2021-08-30

Family

ID=71612981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107663UA SG11202107663UA (en) 2019-01-18 2020-01-16 Lilrb3-binding molecules and uses therefor

Country Status (14)

Country Link
US (1) US20220089723A1 (en)
EP (1) EP3911680A4 (en)
JP (1) JP2022517809A (en)
KR (1) KR20210118116A (en)
CN (1) CN113454123A (en)
AU (1) AU2020209367A1 (en)
BR (1) BR112021014102A2 (en)
CA (1) CA3126295A1 (en)
EA (1) EA202192008A1 (en)
IL (1) IL284781A (en)
MX (1) MX2021008507A (en)
SG (1) SG11202107663UA (en)
TW (1) TW202031685A (en)
WO (1) WO2020146946A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020325770B2 (en) * 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5947727B2 (en) * 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Immunomodulation with anti-ILT5 antibodies and ILT5-binding antibody fragments
EP2525813B1 (en) * 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP3256163A4 (en) * 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Also Published As

Publication number Publication date
TW202031685A (en) 2020-09-01
CN113454123A (en) 2021-09-28
EP3911680A1 (en) 2021-11-24
BR112021014102A2 (en) 2021-09-21
EP3911680A4 (en) 2022-09-07
KR20210118116A (en) 2021-09-29
EA202192008A1 (en) 2021-10-21
US20220089723A1 (en) 2022-03-24
MX2021008507A (en) 2021-09-21
JP2022517809A (en) 2022-03-10
CA3126295A1 (en) 2020-07-23
WO2020146946A1 (en) 2020-07-23
AU2020209367A1 (en) 2021-08-19
IL284781A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
IL269534A (en) Chimeric molecules and uses thereof
EP3672991A4 (en) Anti-cd137 molecules and use thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
IL287765A (en) Tigit and pd-1/tigit-binding molecules
IL278832A (en) Optimized gp41-binding molecules and uses thereof
EP3589290A4 (en) Translatable molecules and synthesis thereof
ZA202105847B (en) Mtroc modulators and uses thereof
GB2595980B (en) Anti-TCR antibody molecules and uses thereof
IL289415A (en) Claudin-6 binding molecules and uses thereof
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
SG11202006459XA (en) Proteinaceous molecules and uses therefor
GB2591554B (en) Composiitons and methods and uses relating thereto
IL278019A (en) Trans-splicing molecules
GB202208378D0 (en) Anti-tcr antibody molecules and uses thereof
EP3630732A4 (en) Method and molecules
GB201812561D0 (en) Biomarkers and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
EP4006048A4 (en) Novel micropeptide hmmw and application thereof
GB2598218B (en) Anti-TCR antibody molecules and uses thereof
IL284781A (en) Lilrb3-binding molecules and uses therefor
IL289266A (en) Novel molecules
IL280369A (en) New myokines and uses thereof
GB201819125D0 (en) Biomarkers and uses thereof
IL285585A (en) Fcmr-binding molecules and uses thereof